Information about Attana’s presentation at Stora Aktiedagen streamed live on December 2[nd] 09:00-09:30
Attana will participate at Stora Aktiedagen where CEO Teodor Aastrup will give a 20-minute company presentation followed by a 10-minute Q&A session. Both will be live streamed on December 2nd from 09:00 to 09:30.
The presentation will focus on where Attana stands today, where the company is heading and the plan for getting there. This includes a presentation of the exciting projects planned for 2021, enabled by the upcoming rights issue.
- Attana in short
– Attana’s product and service offering
- Recent milestones
– Important milestones during 2020
- Upcoming rights issue
– Details regarding the upcoming rights issue
- Action plan 2021
– Projects planned for 2021, and where they will take Attana going forward
Follow the presentation here.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact email@example.com
Surgical Science offentliggör avsikt att genomföra en riktad nyemission
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, JAPAN ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV INFORMATIONEN SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA REGI...
Surgical Science announces intention to carry out a directed share issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PL...
Surgical Science har ingått avtal om förvärv av bolag med verksamhet inom robotkirurgi
Surgical Science Sweden AB (publ) (”Surgical Science” eller "Bolaget”) har tecknat ett villkorat avtal om att förvärva samtliga aktier i Mimic Technologies Inc. (”Mimic”) för en initial köpeskilling om 18 mUSD (ca 150 MSEK) på kassa- och skuldfri basis. Därutöver kan maximalt 15,6 mUSD (ca 130 MSEK)...
Surgical Science has entered into an agreement to acquire a company within the robotic surgery segment
Surgical Science Sweden AB (publ) ("Surgical Science" or the "Company") has entered into a conditional agreement to acquire all shares outstanding of Mimic Technologies Inc. (“Mimic”) for an initial consideration of USD 18.0 million (approximately SEK 150 million) on a cash and debt-free basis. In a...